The impact of mitochondrial DNA and nuclear genes related to mitochondrial functioning on the risk of Parkinson's disease

Current Genomics

Volumn 14, Issue 8, 2013, Pages 543-559

  Gaweda Walerych, Katarzyna ^a   Zekanowski, Cezary ^a  

^a MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Association studies; Mitochondrial dysfunction; mtDNA haplogroups; Nuclear genes; Parkinson's disease; Polymorphism

Indexed keywords

MITOCHONDRIAL DNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; REACTIVE OXYGEN METABOLITE;

BIOGENESIS; BLOOD BRAIN BARRIER; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA METHYLATION; DNA REPLICATION; DNA TRANSCRIPTION; ENVIRONMENTAL FACTOR; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; META ANALYSIS (TOPIC); NONHUMAN; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PARKINSON DISEASE; REVIEW; SOMATIC MUTATION;

EID: 84894098825     PISSN: 13892029     EISSN: 18755488     Source Type: Journal    
DOI: 10.2174/1389202914666131210211033     Document Type: Review

References (238)

1. Samii, A.; Nutt, J.G.; Ransom, B.R. Parkinson's disease. Lancet, 2004, 363, 1783-1793.
2. Fearnley, J.M.; Lees, A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain, 1991, 114 (Pt 5), 2283-2301.
3. van Nuenen, B.F.; van Eimeren, T.; van der Vegt, J.P.; Buhmann, C.; Klein, C.; Bloem, B.R.; Siebner, H.R. Mapping preclinical compensation in Parkinson's disease: an imaging genomics approach. Mov. Disord., 2009, 24 Suppl 2, S703-710.
4. Braak, H.; Del Tredici, K.; Rub, U.; de Vos, R.A.; Jansen Steur, E.N.; Braak, E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging, 2003, 24, 197-211.
5. Hawkes, C.H. The prodromal phase of sporadic Parkinson's disease: does it exist and if so how long is it? Mov Disord., 2008, 23, 1799-1807.
6. Jankovic, J. Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry., 2008, 79, 368-376.
7. Langston, J.W. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann. Neurol., 2006, 59, 591-596.
8. Selikhova, M.; Williams, D.R.; Kempster, P.A.; Holton, J.L.; Revesz, T.; Lees, A.J. A clinico-pathological study of subtypes in Parkinson's disease. Brain, 2009, 132, 2947-2957.
9. Obeso, J.A.; Rodriguez-Oroz, M.C.; Goetz, C.G.; Marin, C.; Kordower, J.H.; Rodriguez, M.; Hirsch, E.C.; Farrer, M.; Schapira, A.H.; Halliday, G. Missing pieces in the Parkinson's disease puzzle. Nat. Med., 2010, 16, 653-661.
10. Elbaz, A.; Bower, J.H.; Maraganore, D.M.; McDonnell, S.K.; Peterson, B.J.; Ahlskog, J.E.; Schaid, D.J.; Rocca, W.A. Risk tables for parkinsonism and Parkinson's disease. J. Clin. Epidemiol., 2002, 55, 25-31.
11. Abou-Sleiman, P.M.; Muqit, M.M.; Wood, N.W. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat. Rev. Neurosci., 2006, 7, 207-219.
12. Exner, N.; Lutz, A.K.; Haass, C.; Winklhofer, K.F. Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO. J., 2012, 31, 3038-3062.
13. Pilsl, A.; Winklhofer, K.F. Parkin, PINK1 and mitochondrial integrity: emerging concepts of mitochondrial dysfunction in Parkinson's disease. Acta. Neuropathol., 2012, 123, 173-188.
14. Gaweda-Walerych, K.; Zekanowski, C. Integrated pathways of parkin control over mitochondrial maintenance-relevance to Parkinson's disease pathogenesis. Acta. Neurobiol. Exp. (Wars), 2013, 73, 199-224.
15. Sai, Y.; Zou, Z.; Peng, K.; Dong, Z. The Parkinson's diseaserelated genes act in mitochondrial homeostasis. Neurosci. Biobehav. Rev., 2012, 36, 2034-2043.
16. Thomas, K.J.; McCoy, M.K.; Blackinton, J.; Beilina, A.; van der Brug, M.; Sandebring, A.; Miller, D.; Maric, D.; Cedazo-Minguez, A.; Cookson, M.R. DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy. Hum. Mol. Genet., 2011, 20, 40-50.
17. Joselin, A.P.; Hewitt, S.J.; Callaghan, S.M.; Kim, R.H.; Chung, Y.H.; Mak, T.W.; Shen, J.; Slack, R.S.; Park, D.S. ROS-dependent regulation of Parkin and DJ-1 localization during oxidative stress in neurons. Hum. Mol. Genet., 2012, 21, 4888-4903.
18. Kuroda, Y.; Mitsui, T.; Kunishige, M.; Shono, M.; Akaike, M.; Azuma, H.; Matsumoto, T. Parkin enhances mitochondrial biogenesis in proliferating cells. Hum. Mol. Genet., 2006, 15, 883-895.
19. Rothfuss, O.; Fischer, H.; Hasegawa, T.; Maisel, M.; Leitner, P.; Miesel, F.; Sharma, M.; Bornemann, A.; Berg, D.; Gasser, T.; Patenge, N. Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair. Hum. Mol. Genet., 2009, 18, 3832-3850.
20. Rideout, H.J.; Stefanis, L. The Neurobiology of LRRK2 and its Role in the Pathogenesis of Parkinson's Disease. Neurochem. Res., 2013
21. Mullin, S.; Schapira, A. Alpha-synuclein and mitochondrial dysfunction in Parkinson's disease. Mol. Neurobiol., 2013, 47, 587-597.
22. Calvo, S.E.; Mootha, V.K. The mitochondrial proteome and human disease. Annu. Rev. Genomics. Hum. Genet., 2010, 11, 25-44.
23. Meisinger, C.; Sickmann, A.; Pfanner, N. The mitochondrial proteome: from inventory to function. Cell, 2008, 134, 22-24.
24. Lill, C.M.; Roehr, J.T.; McQueen, M.B.; Kavvoura, F.K.; Bagade, S.; Schjeide, B.M.; Schjeide, L.M.; Meissner, E.; Zauft, U.; Allen, N.C.; Liu, T.; Schilling, M.; Anderson, K.J.; Beecham, G.; Berg, D.; Biernacka, J.M.; Brice, A.; DeStefano, A.L.; Do, C.B.; Eriksson, N.; Factor, S.A.; Farrer, M.J.; Foroud, T.; Gasser, T.; Hamza, T.; Hardy, J.A.; Heutink, P.; Hill-Burns, E.M.; Klein, C.; Latourelle, J.C.; Maraganore, D.M.; Martin, E.R.; Martinez, M.; Myers, R.H.; Nalls, M.A.; Pankratz, N.; Payami, H.; Satake, W.; Scott, W.K.; Sharma, M.; Singleton, A.B.; Stefansson, K.; Toda, T.; Tung, J.Y.; Vance, J.; Wood, N.W.; Zabetian, C.P.; Young, P.; Tanzi, R.E.; Khoury, M.J.; Zipp, F.; Lehrach, H.; Ioannidis, J.P.; Bertram, L. Comprehensive research synopsis and systematic metaanalyses in Parkinson's disease genetics: The PDGene database, http://www.pdgene.org/,. PLoS. Genet., 2012, 8, e1002548.
25. Warner, T.T.; Schapira, A.H. Genetic and environmental factors in the cause of Parkinson's disease. Ann Neurol, 2003, 53 Suppl 3, S16-23; discussion S23-15.
26. Fujioka, S.; Wszolek, Z.K. Update on genetics of parkinsonism. Neurodegener. Dis., 2012, 10, 257-260.
27. Braak, H.; Del Tredici, K. Poor and protracted myelination as a contributory factor to neurodegenerative disorders. Neurobiol. Aging., 2004, 25, 19-23.
28. Chung, C.Y.; Seo, H.; Sonntag, K.C.; Brooks, A.; Lin, L.; Isacson, O. Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum. Mol. Genet., 2005, 14, 1709-1725.
29. Greene, J.G.; Dingledine, R.; Greenamyre, J.T. Gene expression profiling of rat midbrain dopamine neurons: implications for selective vulnerability in parkinsonism. Neurobiol Dis, 2005, 18, 19-31.
30. Grimm, J.; Mueller, A.; Hefti, F.; Rosenthal, A. Molecular basis for catecholaminergic neuron diversity. Proc. Natl. Acad. Sci. U S A., 2004, 101, 13891-13896.
31. Chan, C.S.; Guzman, J.N.; Ilijic, E.; Mercer, J.N.; Rick, C.; Tkatch, T.; Meredith, G.E.; Surmeier, D.J. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature, 2007, 447, 1081-1086.
32. Guzman, J.N.; Sanchez-Padilla, J.; Wokosin, D.; Kondapalli, J.; Ilijic, E.; Schumacker, P.T.; Surmeier, D.J. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature, 2010, 468, 696-700.
33. Drozak, J.; Bryla, J. Dopamine: not just a neurotransmitter (in Polish). Postepy. Hig. Med. Dosw., 2005, 59, 405-420.
34. Bender, A.; Krishnan, K.J.; Morris, C.M.; Taylor, G.A.; Reeve, A.K.; Perry, R.H.; Jaros, E.; Hersheson, J.S.; Betts, J.; Klopstock, T.; Taylor, R.W.; Turnbull, D.M. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet., 2006
35. Coskun, P.; Wyrembak, J.; Schriner, S.E.; Chen, H.W.; Marciniack, C.; Laferla, F.; Wallace, D.C. A mitochondrial etiology of Alzheimer and Parkinson disease. Biochem. Biophys. Acta., 2012, 1820, 553-564.
36. Sangar, V.; Eddy, J.A.; Simeonidis, E.; Price, N.D. Mechanistic modeling of aberrant energy metabolism in human disease. Front. Physiol., 2012, 3, 404.
37. Parker, W.D., Jr.; Boyson, S.J.; Parks, J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol., 1989, 26, 719-723.
38. Schapira, A.H.; Cooper, J.M.; Dexter, D.; Clark, J.B.; Jenner, P.; Marsden, C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem., 1990, 54, 823-827.
39. Gu, M.; Owen, A.D.; Toffa, S.E.; Cooper, J.M.; Dexter, D.T.; Jenner, P.; Marsden, C.D.; Schapira, A.H. Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases. J. Neurol. Sci., 1998, 158, 24-29.
40. Parker, W.D., Jr.; Parks, J.K.; Swerdlow, R.H. Complex I deficiency in Parkinson's disease frontal cortex. Brain Res, 2008, 1189, 215-218.
41. Blin, O.; Desnuelle, C.; Rascol, O.; Borg, M.; Peyro Saint Paul, H.; Azulay, J.P.; Bille, F.; Figarella, D.; Coulom, F.; Pellissier, J.F.; et al. Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy. J. Neurol. Sci., 1994, 125, 95-101.
42. Haas, R.H.; Nasirian, F.; Nakano, K.; Ward, D.; Pay, M.; Hill, R.; Shults, C.W. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann. Neurol., 1995, 37, 714-722.
43. Krige, D.; Carroll, M.T.; Cooper, J.M.; Marsden, C.D.; Schapira, A.H. Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. Ann. Neurol., 1992, 32, 782-788.
44. Gu, M.; Cooper, J.M.; Taanman, J.W.; Schapira, A.H. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann. Neurol., 1998, 44, 177-186.
45. Swerdlow, R.H.; Parks, J.K.; Miller, S.W.; Tuttle, J.B.; Trimmer, P.A.; Sheehan, J.P.; Bennett, J.P., Jr.; Davis, R.E.; Parker, W.D., Jr. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann. Neurol., 1996, 40, 663-671.
46. Winkler-Stuck, K.; Kirches, E.; Mawrin, C.; Dietzmann, K.; Lins, H.; Wallesch, C.W.; Kunz, W.S.; Wiedemann, F.R. Re-evaluation of the dysfunction of mitochondrial respiratory chain in skeletal muscle of patients with Parkinson's disease. J. Neural. Transm., 2005, 112, 499-518.
47. Esteves, A.R.; Lu, J.; Rodova, M.; Onyango, I.; Lezi, E.; Dubinsky, R.; Lyons, K.E.; Pahwa, R.; Burns, J.M.; Cardoso, S.M.; Swerdlow, R.H. Mitochondrial respiration and respiration-associated proteins in cell lines created through Parkinson's subject mitochondrial transfer. J. Neurochem., 2010, 113, 674-682.
48. Trimmer, P.A.; Borland, M.K.; Keeney, P.M.; Bennett, J.P., Jr.; Parker, W.D., Jr. Parkinson's disease transgenic mitochondrial cybrids generate Lewy inclusion bodies. J. Neurochem., 2004, 88, 800-812.
49. Langston, J.W.; Forno, L.S.; Tetrud, J.; Reeves, A.G.; Kaplan, J.A.; Karluk, D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol., 1999, 46, 598-605.
50. Bove, J.; Prou, D.; Perier, C.; Przedborski, S. Toxin-induced models of Parkinson's disease. NeuroRx, 2005, 2, 484-494.
51. Betarbet, R.; Sherer, T.B.; MacKenzie, G.; Garcia-Osuna, M.; Panov, A.V.; Greenamyre, J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci., 2000, 3, 1301-1306.
52. Betarbet, R.; Sherer, T.B.; Greenamyre, J.T. Animal models of Parkinson's disease. Bioessays, 2002, 24, 308-318.
53. Sherer, T.B.; Betarbet, R.; Stout, A.K.; Lund, S.; Baptista, M.; Panov, A.V.; Cookson, M.R.; Greenamyre, J.T. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J. Neurosci., 2002, 22, 7006-7015.
54. Betarbet, R.; Canet-Aviles, R.M.; Sherer, T.B.; Mastroberardino, P.G.; McLendon, C.; Kim, J.H.; Lund, S.; Na, H.M.; Taylor, G.; Bence, N.F.; Kopito, R.; Seo, B.B.; Yagi, T.; Yagi, A.; Klinefelter, G.; Cookson, M.R.; Greenamyre, J.T. Intersecting pathways to neurodegeneration in Parkinson's disease: Effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol. Dis., 2006., 22(2), 404-20.
55. Shoffner, J.M.; Brown, M.D.; Torroni, A.; Lott, M.T.; Cabell, M.F.; Mirra, S.S.; Beal, M.F.; Yang, C.C.; Gearing, M.; Salvo, R.; et al. Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients. Genomics, 1993, 17, 171-184.
56. Surh, Y.J.; Kim, H.J. Neurotoxic effects of tetrahydroisoquinolines and underlying mechanisms. Exp. Neurobiol., 2010, 19, 63-70.
57. Landrigan, P.J.; Sonawane, B.; Butler, R.N.; Trasande, L.; Callan, R.; Droller, D. Early environmental origins of neurodegenerative disease in later life. Environ. Health. Perspect., 2005, 113, 1230-1233.
58. Kruse, S.E.; Watt, W.C.; Marcinek, D.J.; Kapur, R.P.; Schenkman, K.A.; Palmiter, R.D. Mice with mitochondrial complex I deficiency develop a fatal encephalomyopathy. Cell. Metab., 2008, 7, 312-320.
59. Quintana, A.; Kruse, S.E.; Kapur, R.P.; Sanz, E.; Palmiter, R.D. Complex I deficiency due to loss of Ndufs4 in the brain results in progressive encephalopathy resembling Leigh syndrome. Proc. Natl. Acad. Sci. U S A, 2010, 107, 10996-11001.
60. Leong, D.W.; Komen, J.C.; Hewitt, C.A.; Arnaud, E.; McKenzie, M.; Phipson, B.; Bahlo, M.; Laskowski, A.; Kinkel, S.A.; Davey, G.M.; Heath, W.R.; Voss, A.K.; Zahedi, R.P.; Pitt, J.J.; Chrast, R.; Sickmann, A.; Ryan, M.T.; Smyth, G.K.; Thorburn, D.R.; Scott, H.S. Proteomic and metabolomic analyses of mitochondrial complex I-deficient mouse model generated by spontaneous B2 short interspersed nuclear element (SINE) insertion into NADH dehydrogenase (ubiquinone) Fe-S protein 4 (Ndufs4) gene. J. Biol. Chem., 2012, 287, 20652-20663.
61. Sterky, F.H.; Hoffman, A.F.; Milenkovic, D.; Bao, B.; Paganelli, A.; Edgar, D.; Wibom, R.; Lupica, C.R.; Olson, L.; Larsson, N.G. Altered dopamine metabolism and increased vulnerability to MPTP in mice with partial deficiency of mitochondrial complex I in dopamine neurons. Hum. Mol. Genet., 2012, 21, 1078-1089.
62. Galter, D.; Pernold, K.; Yoshitake, T.; Lindqvist, E.; Hoffer, B.; Kehr, J.; Larsson, N.G.; Olson, L. MitoPark mice mirror the slow progression of key symptoms and L-DOPA response in Parkinson's disease. Genes. Brain. Behav., 2010, 9, 173-181.
63. Ekstrand, M.I.; Terzioglu, M.; Galter, D.; Zhu, S.; Hofstetter, C.; Lindqvist, E.; Thams, S.; Bergstrand, A.; Hansson, F.S.; Trifunovic, A.; Hoffer, B.; Cullheim, S.; Mohammed, A.H.; Olson, L.; Larsson, N.G. Progressive parkinsonism in mice with respiratorychain-deficient dopamine neurons. Proc. Natl. Acad. Sci. U S A, 2007, 104, 1325-1330.
64. Sterky, F.H.; Lee, S.; Wibom, R.; Olson, L.; Larsson, N.G. Impaired mitochondrial transport and Parkin-independent degeneration of respiratory chain-deficient dopamine neurons in vivo. Proc. Natl. Acad. Sci. U S A, 2011, 108, 12937-12942.
65. Pickrell, A.M.; Pinto, M.; Hida, A.; Moraes, C.T. Striatal dysfunctions associated with mitochondrial DNA damage in dopaminergic neurons in a mouse model of Parkinson's disease. J. Neurosci., 2011, 31, 17649-17658.
66. Song, L.; Shan, Y.; Lloyd, K.C.; Cortopassi, G.A. Mutant Twinkle increases dopaminergic neurodegeneration, mtDNA deletions and modulates Parkin expression. Hum. Mol. Genet., 2012, 21(23), 5147-58.
67. Calvaruso, M.A.; Willems, P.; van den Brand, M.; Valsecchi, F.; Kruse, S.; Palmiter, R.; Smeitink, J.; Nijtmans, L. Mitochondrial complex III stabilizes complex I in the absence of NDUFS4 to provide partial activity. Hum. Mol. Genet., 2012, 21, 115-120.
68. Wallace, D.C.; Brown, M.D.; Lott, M.T. Mitochondrial DNA variation in human evolution and disease. Gene, 1999, 238, 211-230.
69. Finnila, S.; Lehtonen, M.S.; Majamaa, K. Phylogenetic network for European mtDNA. Am. J. Hum. Genet., 2001, 68, 1475-1484.
70. Herrnstadt, C.; Elson, J.L.; Fahy, E.; Preston, G.; Turnbull, D.M.; Anderson, C.; Ghosh, S.S.; Olefsky, J.M.; Beal, M.F.; Davis, R.E.; Howell, N. Reduced-median-network analysis of complete mitochondrial DNA coding-region sequences for the major African, Asian, and European haplogroups. Am. J. Hum. Genet., 2002, 70, 1152-1171.
71. Torroni, A.; Huoponen, K.; Francalacci, P.; Petrozzi, M.; Morelli, L.; Scozzari, R.; Obinu, D.; Savontaus, M.L.; Wallace, D.C. Classification of European mtDNAs from an analysis of three European populations. Genetics, 1996, 144, 1835-1850.
72. Torroni, A.; Richards, M.; Macaulay, V.; Forster, P.; Villems, R.; Norby, S.; Savontaus, M.L.; Huoponen, K.; Scozzari, R.; Bandelt, H.J. mtDNA haplogroups and frequency patterns in Europe. Am. J. Hum. Genet., 2000, 66, 1173-1177.
73. Gomez-Duran, A.; Pacheu-Grau, D.; Lopez-Gallardo, E.; Diez-Sanchez, C.; Montoya, J.; Lopez-Perez, M.J.; Ruiz-Pesini, E. Unmasking the causes of multifactorial disorders: OXPHOS differences between mitochondrial haplogroups. Hum. Mol. Genet., 2010, 19, 3343-3353.
74. Kong, Q.P.; Yao, Y.G.; Sun, C.; Bandelt, H.J.; Zhu, C.L.; Zhang, Y.P. Phylogeny of east Asian mitochondrial DNA lineages inferred from complete sequences. Am. J. Hum. Genet., 2003, 73, 671-676.
75. Niemi, A.K.; Moilanen, J.S.; Tanaka, M.; Hervonen, A.; Hurme, M.; Lehtimaki, T.; Arai, Y.; Hirose, N.; Majamaa, K. A combination of three common inherited mitochondrial DNA polymorphisms promotes longevity in Finnish and Japanese subjects. Eur. J. Hum. Genet., 2005, 13, 166-170.
76. Silva, W.A., Jr.; Bonatto, S.L.; Holanda, A.J.; Ribeiro-Dos-Santos, A.K.; Paixao, B.M.; Goldman, G.H.; Abe-Sandes, K.; Rodriguez-Delfin, L.; Barbosa, M.; Paco-Larson, M.L.; Petzl-Erler, M.L.; Valente, V.; Santos, S.E.; Zago, M.A. Mitochondrial genome diversity of Native Americans supports a single early entry of founder populations into America. Am. J. Hum. Genet., 2002, 71, 187-192.
77. Tanaka, M.; Takeyasu, T.; Fuku, N.; Li-Jun, G.; Kurata, M. Mitochondrial genome single nucleotide polymorphisms and their phenotypes in the Japanese. Ann. N. Y. Acad. Sci., 2004, 1011, 7-20.
78. Swerdlow, R.H.; Parks, J.K.; Davis, J.N., 2nd; Cassarino, D.S.; Trimmer, P.A.; Currie, L.J.; Dougherty, J.; Bridges, W.S.; Bennett, J.P., Jr.; Wooten, G.F.; Parker, W.D. Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family. Ann Neurol, 1998, 44, 873-881.
79. Wooten, G.F.; Currie, L.J.; Bennett, J.P.; Harrison, M.B.; Trugman, J.M.; Parker, W.D.; Jr. Maternal inheritance in Parkinson's disease. Ann. Neurol., 1997, 41, 265-268.
80. Simon, D.K.; Pankratz, N.; Kissell, D.K.; Pauciulo, M.W.; Halter, C.A.; Rudolph, A.; Pfeiffer, R.F.; Nichols, W.C.; Foroud, T. Maternal inheritance and mitochondrial DNA variants in familial Parkinson's disease. BMC. Med. Genet., 2010, 11, 53.
81. Simon, D.K.; Mayeux, R.; Marder, K.; Kowall, N.W.; Beal, M.F.; Johns, D.R. Mitochondrial DNA mutations in complex I and tRNA genes in Parkinson's disease. Neurology, 2000, 54, 703-709.
82. Vives-Bauza, C.; Andreu, A.L.; Manfredi, G.; Beal, M.F.; Janetzky, B.; Gruenewald, T.H.; Lin, M.T. Sequence analysis of the entire mitochondrial genome in Parkinson's disease. Biochem. Biophys. Res. Commun., 2002, 290, 1593-1601.
83. Brown, M.D.; Shoffner, J.M.; Kim, Y.L.; Jun, A.S.; Graham, B.H.; Cabell, M.F.; Gurley, D.S.; Wallace, D.C. Mitochondrial DNA sequence analysis of four Alzheimer's and Parkinson's disease patients. Am. J. Med. Genet., 1996, 61, 283-289.
84. Ross, O.A.; McCormack, R.; Maxwell, L.D.; Duguid, R.A.; Quinn, D.J.; Barnett, Y.A.; Rea, I.M.; El-Agnaf, O.M.; Gibson, J.M.; Wallace, A.; Middleton, D.; Curran, M.D. mt4216C variant in linkage with the mtDNA TJ cluster may confer a susceptibility to mitochondrial dysfunction resulting in an increased risk of Parkinson's disease in the Irish. Exp. Gerontol., 2003, 38, 397-405.
85. Huerta, C.; Castro, M.G.; Coto, E.; Blazquez, M.; Ribacoba, R.; Guisasola, L.M.; Salvador, C.; Martinez, C.; Lahoz, C.H.; Alvarez, V. Mitochondrial DNA polymorphisms and risk of Parkinson's disease in Spanish population. J. Neurol. Sci., 2005, 236, 49-54.
86. Autere, J.; Moilanen, J.S.; Finnila, S.; Soininen, H.; Mannermaa, A.; Hartikainen, P.; Hallikainen, M.; Majamaa, K. Mitochondrial DNA polymorphisms as risk factors for Parkinson's disease and Parkinson's disease dementia. Hum. Genet., 2004, 115, 29-35.
87. Pyle, A.; Foltynie, T.; Tiangyou, W.; Lambert, C.; Keers, S.M.; Allcock, L.M.; Davison, J.; Lewis, S.J.; Perry, R.H.; Barker, R.; Burn, D.J.; Chinnery, P.F. Mitochondrial DNA haplogroup cluster UKJT reduces the risk of PD. Ann. Neurol., 2005, 57, 564-567.
88. Ghezzi, D.; Marelli, C.; Achilli, A.; Goldwurm, S.; Pezzoli, G.; Barone, P.; Pellecchia, M.T.; Stanzione, P.; Brusa, L.; Bentivoglio, A.R.; Bonuccelli, U.; Petrozzi, L.; Abbruzzese, G.; Marchese, R.; Cortelli, P.; Grimaldi, D.; Martinelli, P.; Ferrarese, C.; Garavaglia, B.; Sangiorgi, S.; Carelli, V.; Torroni, A.; Albanese, A.; Zeviani, M. Mitochondrial DNA haplogroup K is associated with a lower risk of Parkinson's disease in Italians. Eur. J. Hum. Genet., 2005, 13, 748-752.
89. van der Walt, J.M.; Nicodemus, K.K.; Martin, E.R.; Scott, W.K.; Nance, M.A.; Watts, R.L.; Hubble, J.P.; Haines, J.L.; Koller, W.C.; Lyons, K.; Pahwa, R.; Stern, M.B.; Colcher, A.; Hiner, B.C.; Jankovic, J.; Ondo, W.G.; Allen, F.H., Jr.; Goetz, C.G.; Small, G.W.; Mastaglia, F.; Stajich, J.M.; McLaurin, A.C.; Middleton, L.T.; Scott, B.L.; Schmechel, D.E.; Pericak-Vance, M.A.; Vance, J.M. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am. J. Hum. Genet., 2003, 72, 804-811.
90. Khusnutdinova, E.; Gilyazova, I.; Ruiz-Pesini, E.; Derbeneva, O.; Khusainova, R.; Khidiyatova, I.; Magzhanov, R.; Wallace, D.C. A mitochondrial etiology of neurodegenerative diseases: evidence from Parkinson's disease. Ann. N. Y. Acad. Sci., 2008, 1147, 1-20.
91. Mehta, P.; Mellick, G.D.; Rowe, D.B.; Halliday, G.M.; Jones, M.M.; Manwaring, N.; Vandebona, H.; Silburn, P.A.; Wang, J.J.; Mitchell, P.; Sue, C.M. Mitochondrial DNA haplogroups J and K are not protective for Parkinson's disease in the Australian community. Mov. Disord., 2009, 24, 290-292.
92. Latsoudis, H.; Spanaki, C.; Chlouverakis, G.; Plaitakis, A. Mitochondrial DNA polymorphisms and haplogroups in Parkinson's disease and control individuals with a similar genetic background. J. Hum. Genet., 2008, 53, 349-356.
93. Gaweda-Walerych, K.; Maruszak, A.; Safranow, K.; Bialecka, M.; Klodowska-Duda, G.; Czyzewski, K.; Slawek, J.; Rudzinska, M.; Styczynska, M.; Opala, G.; Drozdzik, M.; Canter, J.A.; Barcikowska, M.; Zekanowski, C. Mitochondrial DNA haplogroups and subhaplogroups are associated with Parkinson's disease risk in a Polish PD cohort. J. Neural. Transm., 2008, 115, 1521-1526.
94. Ruiz-Pesini, E.; Lapena, A.C.; Diez-Sanchez, C.; Perez-Martos, A.; Montoya, J.; Alvarez, E.; Diaz, M.; Urries, A.; Montoro, L.; Lopez-Perez, M.J.; Enriquez, J.A. Human mtDNA haplogroups associated with high or reduced spermatozoa motility. Am. J. Hum. Genet., 2000, 67, 682-696.
95. Ruiz-Pesini, E.; Mishmar, D.; Brandon, M.; Procaccio, V.; Wallace, D.C. Effects of purifying and adaptive selection on regional variation in human mtDNA. Science, 2004, 303, 223-226.
96. Wallace, D.C. The mitochondrial genome in human adaptive radiation and disease: on the road to therapeutics and performance enhancement. Gene, 2005, 354, 169-180.
97. Montiel-Sosa, F.; Ruiz-Pesini, E.; Enriquez, J.A.; Marcuello, A.; Diez-Sanchez, C.; Montoya, J.; Wallace, D.C.; Lopez-Perez, M.J. Differences of sperm motility in mitochondrial DNA haplogroup U sublineages. Gene, 2006, 368, 21-27.
98. Sun, C.; Kong, Q.P.; Zhang, Y.P. The role of climate in human mitochondrial DNA evolution: a reappraisal. Genomics, 2007, 89, 338-342.
99. Amo, T.; Brand, M.D. Were inefficient mitochondrial haplogroups selected during migrations of modern humans? A test using modular kinetic analysis of coupling in mitochondria from cybrid cell lines. Biochem. J., 2007, 404, 345-351.
100. Elson, J.L.; Turnbull, D.M.; Taylor, R.W. Testing the adaptive selection of human mtDNA haplogroups: an experimental bioenergetics approach. Biochem. J., 2007, 404, e3-5.
101. Kivisild, T.; Shen, P.; Wall, D.P.; Do, B.; Sung, R.; Davis, K.; Passarino, G.; Underhill, P.A.; Scharfe, C.; Torroni, A.; Scozzari, R.; Modiano, D.; Coppa, A.; de Knijff, P.; Feldman, M.; Cavalli-Sforza, L.L.; Oefner, P.J. The role of selection in the evolution of human mitochondrial genomes. Genetics, 2006, 172, 373-387.
102. Maruszak, A.; Safranow, K.; Branicki, W.; Gaweda-Walerych, K.; Pospiech, E.; Gabryelewicz, T.; Canter, J.A.; Barcikowska, M.; Zekanowski, C. The impact of mitochondrial and nuclear DNA variants on late-onset Alzheimer's disease risk. J. Alzheimers. Dis., 2011, 27, 197-210.
103. Niemi, A.K.; Hervonen, A.; Hurme, M.; Karhunen, P.J.; Jylha, M.; Majamaa, K. Mitochondrial DNA polymorphisms associated with longevity in a Finnish population. Hum. Genet., 2003, 112, 29-33.
104. Dominguez-Garrido, E.; Martinez-Redondo, D.; Martin-Ruiz, C.; Gomez-Duran, A.; Ruiz-Pesini, E.; Madero, P.; Tamparillas, M.; Montoya, J.; von Zglinicki, T.; Diez-Sanchez, C.; Lopez-Perez, M.J. Association of mitochondrial haplogroup J and mtDNA oxidative damage in two different North Spain elderly populations. Biogerontology, 2009, 10, 435-442.
105. De Benedictis, G.; Rose, G.; Carrieri, G.; De Luca, M.; Falcone, E.; Passarino, G.; Bonafe, M.; Monti, D.; Baggio, G.; Bertolini, S.; Mari, D.; Mattace, R.; Franceschi, C. Mitochondrial DNA inherited variants are associated with successful aging and longevity in humans. Faseb. J., 1999, 13, 1532-1536.
106. Ross, O.A.; McCormack, R.; Curran, M.D.; Duguid, R.A.; Barnett, Y.A.; Rea, I.M.; Middleton, D. Mitochondrial DNA polymorphism: its role in longevity of the Irish population. Exp. Gerontol., 2001, 36, 1161-1178.
107. Rego-Perez, I.; Fernandez-Moreno, M.; Fernandez-Lopez, C.; Arenas, J.; Blanco, F.J. Mitochondrial DNA haplogroups: role in the prevalence and severity of knee osteoarthritis. Arthritis Rheum., 2008, 58, 2387-2396.
108. Rego, I.; Fernandez-Moreno, M.; Fernandez-Lopez, C.; Gomez-Reino, J.J.; Gonzalez, A.; Arenas, J.; Blanco, F.J. Role of European mitochondrial DNA haplogroups in the prevalence of hip osteoarthritis in Galicia, Northern Spain. Ann. Rheum. Dis., 2010, 69, 210-213.
109. Marcuello, A.; Martinez-Redondo, D.; Dahmani, Y.; Casajus, J.A.; Ruiz-Pesini, E.; Montoya, J.; Lopez-Perez, M.J.; Diez-Sanchez, C. Human mitochondrial variants influence on oxygen consumption. Mitochondrion, 2009, 9(1), 27-30.
110. Martinez-Redondo, D.; Marcuello, A.; Casajus, J.A.; Ara, I.; Dahmani, Y.; Montoya, J.; Ruiz-Pesini, E.; Lopez-Perez, M.J.; Diez-Sanchez, C. Human mitochondrial haplogroup H: the highest VO2max consumer-is it a paradox? Mitochondrion, 2010, 10, 102-107.
111. Fernandez-Moreno, M.; Tamayo, M.; Soto-Hermida, A.; Mosquera, A.; Oreiro, N.; Fernandez-Lopez, C.; Fernandez, J.L.; Rego-Perez, I.; Blanco, F.J. mtDNA haplogroup J Modulates telomere length and Nitric Oxide production. BMC Musculoskelet. Disord., 2011, 12, 283.
112. Bellizzi, D.; D'Aquila, P.; Giordano, M.; Montesanto, A.; Passarino, G. Global DNA methylation levels are modulated by mitochondrial DNA variants. Epigenomics, 2012, 4, 17-27.
113. Kenney, M.C.; Chwa, M.; Atilano, S.R.; Pavlis, J.M.; Falatoonzadeh, P.; Ramirez, C.; Malik, D.; Hsu, T.; Woo, G.; Soe, K.; Nesburn, A.B.; Boyer, D.S.; Kuppermann, B.D.; Jazwinski, S.M.; Miceli, M.V.; Wallace, D.C.; Udar, N. Mitochondrial DNA variants mediate energy production and expression levels for CFH, C3 and EFEMP1 genes: implications for age-related macular degeneration. PLoS One, 2013, 8, e54339.
114. Hudson, G.; Faini, D.; Stutt, A.; Eccles, M.; Robinson, L.; Burn, D.J.; Chinnery, P.F. No evidence of substantia nigra telomere shortening in Parkinson's disease. Neurobiol Aging, 2011, 32, 2107 e2103-2105.
115. Maeda, T.; Guan, J.Z.; Koyanagi, M.; Higuchi, Y.; Makino, N. Aging-associated alteration of telomere length and subtelomeric status in female patients with Parkinson's disease. J. Neurogenet., 2012, 26, 245-251.
116. Watfa, G.; Dragonas, C.; Brosche, T.; Dittrich, R.; Sieber, C.C.; Alecu, C.; Benetos, A.; Nzietchueng, R. Study of telomere length and different markers of oxidative stress in patients with Parkinson's disease. J. Nutr. Health Aging, 2011, 15, 277-281.
117. Eerola, J.; Kananen, L.; Manninen, K.; Hellstrom, O.; Tienari, P.J.; Hovatta, I. No evidence for shorter leukocyte telomere length in Parkinson's disease patients. J. Gerontol. A. Biol. Sci. Med. Sci., 2010, 65, 1181-1184.
118. Wang, H.; Chen, H.; Gao, X.; McGrath, M.; Deer, D.; De Vivo, I.; Schwarzschild, M.A.; Ascherio, A. Telomere length and risk of Parkinson's disease. Mov. Disord., 2008, 23, 302-305.
119. Brown, M.D.; Starikovskaya, E.; Derbeneva, O.; Hosseini, S.; Allen, J.C.; Mikhailovskaya, I.E.; Sukernik, R.I.; Wallace, D.C. The role of mtDNA background in disease expression: a new primary LHON mutation associated with Western Eurasian haplogroup J. Hum. Genet., 2002, 110, 130-138.
120. Brown, M.D.; Sun, F.; Wallace, D.C. Clustering of Caucasian Leber hereditary optic neuropathy patients containing the 11778 or 14484 mutations on an mtDNA lineage. Am. J. Hum. Genet., 1997, 60, 381-387.
121. Arning, L.; Haghikia, A.; Taherzadeh-Fard, E.; Saft, C.; Andrich, J.; Pula, B.; Hoxtermann, S.; Wieczorek, S.; Akkad, D.A.; Perrech, M.; Gold, R.; Epplen, J.T.; Chan, A. Mitochondrial haplogroup H correlates with ATP levels and age at onset in Huntington disease. J. Mol. Med. (Berl), 2010, 88, 431-436.
122. Baudouin, S.V.; Saunders, D.; Tiangyou, W.; Elson, J.L.; Poynter, J.; Pyle, A.; Keers, S.; Turnbull, D.M.; Howell, N.; Chinnery, P.F. Mitochondrial DNA and survival after sepsis: a prospective study. Lancet, 2005, 366, 2118-2121.
123. Rosa, A.; Fonseca, B.V.; Krug, T.; Manso, H.; Gouveia, L.; Albergaria, I.; Gaspar, G.; Correia, M.; Viana-Baptista, M.; Simoes, R.M.; Pinto, A.N.; Taipa, R.; Ferreira, C.; Fontes, J.R.; Silva, M.R.; Gabriel, J.P.; Matos, I.; Lopes, G.; Ferro, J.M.; Vicente, A.M.; Oliveira, S.A. Mitochondrial haplogroup H1 is protective for ischemic stroke in Portuguese patients. BMC Med. Genet., 2008, 9, 57.
124. Hudson, G.; Nalls, M.; Evans, J.R.; Breen, D.P.; Winder-Rhodes, S.; Morrison, K.E.; Morris, H.R.; Williams-Gray, C.H.; Barker, R.A.; Singleton, A.B.; Hardy, J.; Wood, N.E.; Burn, D.J.; Chinnery, P.F. Two-stage association study and meta-analysis of mitochondrial DNA variants in Parkinson disease. Neurology, 2013, 80, 2042-2048.
125. Maruszak, A.; Canter, J.A.; Styczynska, M.; Zekanowski, C.; Barcikowska, M. Mitochondrial haplogroup H and Alzheimer's disease-Is there a connection? Neurobiol. Aging, 2008, 30(11), 1749-1755.
126. Coto, E.; Gomez, J.; Alonso, B.; Corao, A.I.; Diaz, M.; Menendez, M.; Martinez, C.; Calatayud, M.T.; Moris, G.; Alvarez, V. Lateonset Alzheimer's disease is associated with mitochondrial DNA 7028C/haplogroup H and D310 poly-C tract heteroplasmy. Neurogenetics, 2011, 12, 345-346.
127. Carelli, V.; Vergani, L.; Bernazzi, B.; Zampieron, C.; Bucchi, L.; Valentino, M.; Rengo, C.; Torroni, A.; Martinuzzi, A. Respiratory function in cybrid cell lines carrying European mtDNA haplogroups: implications for Leber's hereditary optic neuropathy. Biochim. Biophys. Acta, 2002, 1588, 7-14.
128. Amo, T.; Yadava, N.; Oh, R.; Nicholls, D.G.; Brand, M.D. Experimental assessment of bioenergetic differences caused by the common European mitochondrial DNA haplogroups H and T. Gene, 2008, 411, 69-76.
129. Mueller, E.E.; Brunner, S.M.; Mayr, J.A.; Stanger, O.; Sperl, W.; Kofler, B. Functional differences between mitochondrial haplogroup T and haplogroup H in HEK293 cybrid cells. PLoS One, 2012, 7, e52367.
130. Tanaka, M.; Fuku, N.; Nishigaki, Y.; Matsuo, H.; Segawa, T.; Watanabe, S.; Kato, K.; Yokoi, K.; Ito, M.; Nozawa, Y.; Yamada, Y. Women with mitochondrial haplogroup N9a are protected against metabolic syndrome. Diabetes, 2007, 56, 518-521.
131. Fuku, N.; Park, K.S.; Yamada, Y.; Nishigaki, Y.; Cho, Y.M.; Matsuo, H.; Segawa, T.; Watanabe, S.; Kato, K.; Yokoi, K.; Nozawa, Y.; Lee, H.K.; Tanaka, M. Mitochondrial haplogroup N9a confers resistance against type 2 diabetes in Asians. Am. J. Hum. Genet., 2007, 80, 407-415.
132. Takasaki, S. Mitochondrial haplogroups associated with Japanese centenarians, Alzheimer's patients, Parkinson's patients, type 2 diabetic patients and healthy non-obese young males. J. Genet. Genomics, 2009, 36, 425-434.
133. Takasaki, S. Mitochondrial haplogroups associated with Japanese Alzheimer's patients. J. Bioenerg. Biomembr., 2009, 41, 407-410.
134. Hwang, S.; Kwak, S.H.; Bhak, J.; Kang, H.S.; Lee, Y.R.; Koo, B.K.; Park, K.S.; Lee, H.K.; Cho, Y.M. Gene expression pattern in transmitochondrial cytoplasmic hybrid cells harboring type 2 diabetes-associated mitochondrial DNA haplogroups. PLoS. One, 2011, 6, e22116.
135. Lin, T.K.; Lin, H.Y.; Chen, S.D.; Chuang, Y.C.; Chuang, J.H.; Wang, P.W.; Huang, S.T.; Tiao, M.M.; Chen, J.B.; Liou, C.W. The creation of cybrids harboring mitochondrial haplogroups in the Taiwanese population of ethnic Chinese background: an extensive in vitro tool for the study of mitochondrial genomic variations. Oxid. Med. Cell Longev., 2012, 2012, 824275
136. Pesce, V.; Nicassio, L.; Fracasso, F.; Musicco, C.; Cantatore, P.; Gadaleta, M.N. Acetyl-L-carnitine activates the peroxisome proliferator-activated receptor-gamma coactivators PGC-1alpha/PGC-1beta-dependent signaling cascade of mitochondrial biogenesis and decreases the oxidized peroxiredoxins content in old rat liver. Rejuvenation. Res., 2012, 15, 136-139.
137. Lee, H.K.; Song, J.H.; Shin, C.S.; Park, D.J.; Park, K.S.; Lee, K.U.; Koh, C.S. Decreased mitochondrial DNA content in peripheral blood precedes the development of non-insulin-dependent diabetes mellitus. Diabetes Res. Clin. Pract., 1998, 42, 161-167.
138. Picca, A.; Fracasso, F.; Pesce, V.; Cantatore, P.; Joseph, A.M.; Leeuwenburgh, C.; Gadaleta, M.N.; Lezza, A.M. Age-and calorie restriction-related changes in rat brain mitochondrial DNA and TFAM binding. Age (Dordr), 2012, 35(5), 1607-1620
139. Cree, L.M.; Patel, S.K.; Pyle, A.; Lynn, S.; Turnbull, D.M.; Chinnery, P.F.; Walker, M. Age-related decline in mitochondrial DNA copy number in isolated human pancreatic islets. Diabetologia, 2008, 51, 1440-1443.
140. Short, K.R.; Bigelow, M.L.; Kahl, J.; Singh, R.; Coenen-Schimke, J.; Raghavakaimal, S.; Nair, K.S. Decline in skeletal muscle mitochondrial function with aging in humans. Proc. Natl. Acad. Sci. U S A, 2005, 102, 5618-5623.
141. Monickaraj, F.; Aravind, S.; Gokulakrishnan, K.; Sathishkumar, C.; Prabu, P.; Prabu, D.; Mohan, V.; Balasubramanyam, M. Accelerated aging as evidenced by increased telomere shortening and mitochondrial DNA depletion in patients with type 2 diabetes. Mol. Cell. Biochem., 2012, 365, 343-350.
142. Barrientos, A.; Casademont, J.; Cardellach, F.; Estivill, X.; Urbano-Marquez, A.; Nunes, V. Reduced steady-state levels of mitochondrial RNA and increased mitochondrial DNA amount in human brain with aging. Brain. Res. Mol. Brain. Res., 1997, 52, 284-289.
143. Blokhin, A.; Vyshkina, T.; Komoly, S.; Kalman, B. Variations in mitochondrial DNA copy numbers in MS brains. J. Mol. Neurosci., 2008, 35, 283-287.
144. Keeney, P.M.; Quigley, C.K.; Dunham, L.D.; Papageorge, C.M.; Iyer, S.; Thomas, R.R.; Schwarz, K.M.; Trimmer, P.A.; Khan, S.M.; Portell, F.R.; Bergquist, K.E.; Bennett Jr, J.P. Mitochondrial Gene Therapy Augments Mitochondrial Physiology in a Parkinson's Disease Cell Model. Hum. Gene. Ther., 2009, 20(8), 897-907.
145. Borland, M.K.; Mohanakumar, K.P.; Rubinstein, J.D.; Keeney, P.M.; Xie, J.; Capaldi, R.; Dunham, L.D.; Trimmer, P.A.; Bennett, J.P., Jr. Relationships among molecular genetic and respiratory properties of Parkinson's disease cybrid cells show similarities to Parkinson's brain tissues. Biochim. Biophys. Acta., 2009, 1792, 68-74.
146. Iwaasa, M.; Umeda, S.; Ohsato, T.; Takamatsu, C.; Fukuoh, A.; Iwasaki, H.; Shinagawa, H.; Hamasaki, N.; Kang, D. 1-Methyl-4-phenylpyridinium ion, a toxin that can cause parkinsonism, alters branched structures of DNA. J. Neurochem, 2002, 82, 30-37.
147. Umeda, S.; Muta, T.; Ohsato, T.; Takamatsu, C.; Hamasaki, N.; Kang, D. The D-loop structure of human mtDNA is destabilized directly by 1-methyl-4-phenylpyridinium ion (MPP+), a parkinsonism-causing toxin. Eur. J. Biochem., 2000, 267, 200-206.
148. Kraytsberg, Y.; Kudryavtseva, E.; McKee, A.C.; Geula, C.; Kowall, N.W.; Khrapko, K. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat. Genet., 2006, 38, 518-520.
149. Hori, A.; Yoshida, M.; Shibata, T.; Ling, F. Reactive oxygen species regulate DNA copy number in isolated yeast mitochondria by triggering recombination-mediated replication. Nucleic Acids Res., 2009, 37, 749-761.
150. Moreno-Loshuertos, R.; Acin-Perez, R.; Fernandez-Silva, P.; Movilla, N.; Perez-Martos, A.; Rodriguez de Cordoba, S.; Gallardo, M.E.; Enriquez, J.A. Differences in reactive oxygen species production explain the phenotypes associated with common mouse mitochondrial DNA variants. Nat. Genet, 2006, 38, 1261-1268.
151. Lee, H.C.; Wei, Y.H. Mitochondrial biogenesis and mitochondrial DNA maintenance of mammalian cells under oxidative stress. Int. J. Biochem. Cell. Biol., 2005, 37, 822-834.
152. Suissa, S.; Wang, Z.; Poole, J.; Wittkopp, S.; Feder, J.; Shutt, T.E.; Wallace, D.C.; Shadel, G.S.; Mishmar, D. Ancient mtDNA genetic variants modulate mtDNA transcription and replication. PLoS Genet., 2009, 5, e1000474.
153. Scarpulla, R.C. Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol. Rev, 2008, 88, 611-638.
154. Holt, I.J.; Reyes, A. Human Mitochondrial DNA Replication. Cold Spring Harb Perspect. Biol., 2012.
155. Coskun, P.E.; Beal, M.F.; Wallace, D.C. Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc. Natl. Acad. Sci. U S A, 2004, 101, 10726-10731.
156. Simon, D.K.; Lin, M.T.; Zheng, L.; Liu, G.J.; Ahn, C.H.; Kim, L.M.; Mauck, W.M.; Twu, F.; Beal, M.F.; Johns, D.R. Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson's disease. Neurobiol. Aging, 2004, 25, 71-81.
157. Schoeler, S.; Hertel, S.; Haroon, M.F.; Winkler-Stuck, K.; Mawrin, C.; Kirches, E. Absence of major accumulation of mitochondrial ND5 mutations in Parkinson patient muscle. Clin. Neuropathol., 2007, 26, 164-168.
158. Smigrodzki, R.; Parks, J.; Parker, W.D. High frequency of mitochondrial complex I mutations in Parkinson's disease and aging. Neurobiol. Aging, 2004, 25, 1273-1281.
159. Mawrin, C.; Kirches, E.; Krause, G.; Schneider-Stock, R.; Bogerts, B.; Vorwerk, C.K.; Dietzmann, K. Region-specific analysis of mitochondrial DNA deletions in neurodegenerative disorders in humans. Neurosci. Lett., 2004, 357, 111-114.
160. Lin, M.T.; Cantuti-Castelvetri, I.; Zheng, K.; Jackson, K.E.; Tan, Y.B.; Arzberger, T.; Lees, A.J.; Betensky, R.A.; Beal, M.F.; Simon, D.K. Somatic mitochondrial DNA mutations in early parkinson and incidental lewy body disease. Ann. Neurol., 2012, 71, 850-854.
161. Esterbauer, H.; Oberkofler, H.; Krempler, F.; Patsch, W. Human peroxisome proliferator activated receptor gamma coactivator 1 (PPARGC1) gene: cDNA sequence, genomic organization, chromosomal localization, and tissue expression. Genomics, 1999, 62, 98-102.
162. Scarpulla, R.C. Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. Biochim. Biophys. Acta., 2011, 1813, 1269-1278.
163. Scarpulla, R.C. Nuclear control of respiratory gene expression in mammalian cells. J. Cell Biochem., 2006, 97, 673-683.
164. Scarpulla, R.C. Nuclear control of respiratory chain expression by nuclear respiratory factors and PGC-1-related coactivator. Ann. N. Y. Acad. Sci., 2008, 1147, 321-334.
165. Hattori, N.; Yoshino, H.; Tanaka, M.; Suzuki, H.; Mizuno, Y. Genotype in the 24-kDa subunit gene (NDUFV2) of mitochondrial complex I and susceptibility to Parkinson disease. Genomics, 1998, 49, 52-58.
166. Nishioka, K.; Vilarino-Guell, C.; Cobb, S.A.; Kachergus, J.M.; Ross, O.A.; Hentati, E.; Hentati, F.; Farrer, M.J. Genetic variation of the mitochondrial complex I subunit NDUFV2 and Parkinson's disease. Parkinsonism. Relat. Disord., 2010, 16, 686-687.
167. Clark, J.; Reddy, S.; Zheng, K.; Betensky, R.A.; Simon, D.K. Association of PGC-1alpha polymorphisms with age of onset and risk of Parkinson's disease. BMC. Med. Genet., 2011, 12, 69.
168. Ling, C.; Poulsen, P.; Carlsson, E.; Ridderstrale, M.; Almgren, P.; Wojtaszewski, J.; Beck-Nielsen, H.; Groop, L.; Vaag, A. Multiple environmental and genetic factors influence skeletal muscle PGC-1alpha and PGC-1beta gene expression in twins. J. Clin. Invest., 2004, 114, 1518-1526.
169. Deeb, S.S.; Brunzell, J.D. The Role of the PGC1alpha Gly482Ser Polymorphism in Weight Gain due to Intensive Diabetes Therapy. PPAR. Res., 2009, 2009, 649286.
170. Prabhakar, S.; Vinish, M.; Das, C.P.; Anand, A. Occurrence of PARK2 mutations in a never-smoker population with Parkinson's disease in North India. Neuroepidemiology, 2010, 35, 152-159.
171. Ek, J.; Andersen, G.; Urhammer, S.A.; Gaede, P.H.; Drivsholm, T.; Borch-Johnsen, K.; Hansen, T.; Pedersen, O. Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to Type II diabetes mellitus. Diabetologia, 2001, 44, 2220-2226.
172. Vimaleswaran, K.S.; Luan, J.; Andersen, G.; Muller, Y.L.; Wheeler, E.; Brito, E.C.; O'Rahilly, S.; Pedersen, O.; Baier, L.J.; Knowler, W.C.; Barroso, I.; Wareham, N.J.; Loos, R.J.; Franks, P.W. The Gly482Ser genotype at the PPARGC1A gene and elevated blood pressure: a meta-analysis involving 13,949 individuals. J. Appl. Physiol., 2008, 105, 1352-1358.
173. Zheng, B.; Liao, Z.; Locascio, J.J.; Lesniak, K.A.; Roderick, S.S.; Watt, M.L.; Eklund, A.C.; Zhang-James, Y.; Kim, P.D.; Hauser, M.A.; Grunblatt, E.; Moran, L.B.; Mandel, S.A.; Riederer, P.; Miller, R.M.; Federoff, H.J.; Wullner, U.; Papapetropoulos, S.; Youdim, M.B.; Cantuti-Castelvetri, I.; Young, A.B.; Vance, J.M.; Davis, R.L.; Hedreen, J.C.; Adler, C.H.; Beach, T.G.; Graeber, M.B.; Middleton, F.A.; Rochet, J.C.; Scherzer, C.R. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci. Transl. Med., 2010, 2, 52ra73.
174. Shin, J.H.; Ko, H.S.; Kang, H.; Lee, Y.; Lee, Y.I.; Pletinkova, O.; Troconso, J.C.; Dawson, V.L.; Dawson, T.M. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell, 2011, 144, 689-702.
175. Pacelli, C.; De Rasmo, D.; Signorile, A.; Grattagliano, I.; di Tullio, G.; D'Orazio, A.; Nico, B.; Comi, G.P.; Ronchi, D.; Ferranini, E.; Pirolo, D.; Seibel, P.; Schubert, S.; Gaballo, A.; Villani, G.; Cocco, T. Mitochondrial defect and PGC-1alpha dysfunction in parkinassociated familial Parkinson's disease. Biochim. Biophys. Acta., 2011, 1812, 1041-1053.
176. Ciron, C.; Lengacher, S.; Dusonchet, J.; Aebischer, P.; Schneider, B.L. Sustained expression of PGC-1alpha in the rat nigrostriatal system selectively impairs dopaminergic function. Hum. Mol. Genet., 2012, 21, 1861-1876.
177. Jin, J.; Meredith, G.E.; Chen, L.; Zhou, Y.; Xu, J.; Shie, F.S.; Lockhart, P.; Zhang, J. Quantitative proteomic analysis of mitochondrial proteins: relevance to Lewy body formation and Parkinson's disease. Brain Res. Mol. Brain Res., 2005, 134, 119-138.
178. Jin, J.; Hulette, C.; Wang, Y.; Zhang, T.; Pan, C.; Wadhwa, R.; Zhang, J. Proteomic identification of a stress protein, mortalin/ mthsp70/GRP75: relevance to Parkinson disease. Mol. Cell. Proteomics, 2006, 5, 1193-1204.
179. Shi, M.; Jin, J.; Wang, Y.; Beyer, R.P.; Kitsou, E.; Albin, R.L.; Gearing, M.; Pan, C.; Zhang, J. Mortalin: a protein associated with progression of Parkinson disease? J. Neuropathol. Exp. Neurol., 2008, 67, 117-124.
180. Chiasserini, D.; Tozzi, A.; de Iure, A.; Tantucci, M.; Susta, F.; Orvietani, P.L.; Koya, K.; Binaglia, L.; Calabresi, P. Mortalin inhibition in experimental Parkinson's disease. Mov. Disord., 2011, 26, 1639-1647.
181. Burbulla, L.F.; Schelling, C.; Kato, H.; Rapaport, D.; Woitalla, D.; Schiesling, C.; Schulte, C.; Sharma, M.; Illig, T.; Bauer, P.; Jung, S.; Nordheim, A.; Schols, L.; Riess, O.; Kruger, R. Dissecting the role of the mitochondrial chaperone mortalin in Parkinson's disease: functional impact of disease-related variants on mitochondrial homeostasis. Hum. Mol. Genet., 2010, 19, 4437-4452.
182. De Mena, L.; Coto, E.; Sanchez-Ferrero, E.; Ribacoba, R.; Guisasola, L.M.; Salvador, C.; Blazquez, M.; Alvarez, V. Mutational screening of the mortalin gene (HSPA9) in Parkinson's disease. J. Neural. Transm., 2009, 116, 1289-1293.
183. Humphries, A.D.; Streimann, I.C.; Stojanovski, D.; Johnston, A.J.; Yano, M.; Hoogenraad, N.J.; Ryan, M.T. Dissection of the mitochondrial import and assembly pathway for human Tom40. J. Biol. Chem., 2005, 280, 11535-11543.
184. Cruchaga, C.; Nowotny, P.; Kauwe, J.S.; Ridge, P.G.; Mayo, K.; Bertelsen, S.; Hinrichs, A.; Fagan, A.M.; Holtzman, D.M.; Morris, J.C.; Goate, A.M. Association and expression analyses with singlenucleotide polymorphisms in TOMM40 in Alzheimer disease. Arch. Neurol., 2011, 68, 1013-1019.
185. Maruszak, A.; Peplonska, B.; Safranow, K.; Chodakowska-Zebrowska, M.; Barcikowska, M.; Zekanowski, C. TOMM40 rs10524523 polymorphism's role in late-onset Alzheimer's disease and in longevity. J. Alzheimers Dis., 2012, 28, 309-322.
186. Peplonska, B.; Safranow, K.; Gaweda-Walerych, K.; Maruszak, A.; Czyzewski, K.; Rudzinska, M.; Barcikowska, M.; Zekanowski, C. TOMM40 and APOE common genetic variants are not Parkinson's disease risk factors. Neurobiol. Aging, 2013, 34, 2078 e2071-2072.
187. Shutt, T.E.; Shadel, G.S. A compendium of human mitochondrial gene expression machinery with links to disease. Environ. Mol. Mutagen., 2010, 51, 360-379.
188. Gohil, V.M.; Nilsson, R.; Belcher-Timme, C.A.; Luo, B.; Root, D.E.; Mootha, V.K. Mitochondrial and nuclear genomic responses to loss of LRPPRC expression. J. Biol. Chem., 2010, 285, 13742-13747.
189. Mili, S.; Pinol-Roma, S. LRP130, a pentatricopeptide motif protein with a noncanonical RNA-binding domain, is bound in vivo to mitochondrial and nuclear RNAs. Mol. Cell. Biol., 2003, 23, 4972-4982.
190. Rakovic, A.; Grunewald, A.; Voges, L.; Hofmann, S.; Orolicki, S.; Lohmann, K.; Klein, C. PINK1-Interacting Proteins: Proteomic Analysis of Overexpressed PINK1. Parkinsons. Dis., 2011, 2011, 153979.
191. Alam, T.I.; Kanki, T.; Muta, T.; Ukaji, K.; Abe, Y.; Nakayama, H.; Takio, K.; Hamasaki, N.; Kang, D. Human mitochondrial DNA is packaged with TFAM. Nucleic Acids Res., 2003, 31, 1640-1645.
192. Larsson, N.G.; Wang, J.; Wilhelmsson, H.; Oldfors, A.; Rustin, P.; Lewandoski, M.; Barsh, G.S.; Clayton, D.A. Mitochondrial transcription factor A is necessary for mtDNA maintenance and embryogenesis in mice. Nat. Genet., 1998, 18, 231-236.
193. Hayashi, Y.; Yoshida, M.; Yamato, M.; Ide, T.; Wu, Z.; Ochi-Shindou, M.; Kanki, T.; Kang, D.; Sunagawa, K.; Tsutsui, H.; Nakanishi, H. Reverse of age-dependent memory impairment and mitochondrial DNA damage in microglia by an overexpression of human mitochondrial transcription factor a in mice. J. Neurosci., 2008, 28, 8624-8634.
194. Noack, H.; Bednarek, T.; Heidler, J.; Ladig, R.; Holtz, J.; Szibor, M. TFAM-dependent and independent dynamics of mtDNA levels in C2C12 myoblasts caused by redox stress. Biochim. Biophys. Acta., 2006, 1760, 141-150.
195. Bonawitz, N.D.; Clayton, D.A.; Shadel, G.S. Initiation and beyond: multiple functions of the human mitochondrial transcription machinery. Mol. Cell, 2006, 24, 813-825.
196. Alvarez, V.; Corao, A.I.; Sanchez-Ferrero, E.; De Mena, L.; Alonso-Montes, C.; Huerta, C.; Blazquez, M.; Ribacoba, R.; Guisasola, L.M.; Salvador, C.; Garcia-Castro, M.; Coto, E. Mitochondrial transcription factor A (TFAM) gene variation in Parkinson's disease. Neurosci. Lett., 2008, 432, 79-82.
197. Sánchez-Ferrero E, C.E., Blázquez M, Ribacoba R, Guisasola LM, Salvador C, Alvarez V. Mutational screening of the mitochondrial transcription factors B1 and B2 (TFB1M and TFB2M) in Parkinson's disease. Parkinsonism Relat. Disord., 2009, 15, 468-470.
198. Gaweda-Walerych, K.; Safranow, K.; Maruszak, A.; Bialecka, M.; Klodowska-Duda, G.; Czyzewski, K.; Slawek, J.; Rudzinska, M.; Styczynska, M.; Opala, G.; Drozdzik, M.; Kurzawski, M.; Szczudlik, A.; Canter, J.A.; Barcikowska, M.; Zekanowski, C. Mitochondrial transcription factor A variants and the risk of Parkinson's disease. Neurosci. Lett., 2010, 469, 24-29.
199. Belin, A.C.; Bjork, B.F.; Westerlund, M.; Galter, D.; Sydow, O.; Lind, C.; Pernold, K.; Rosvall, L.; Hakansson, A.; Winblad, B.; Nissbrandt, H.; Graff, C.; Olson, L. Association study of two genetic variants in mitochondrial transcription factor A (TFAM) in Alzheimer's and Parkinson's disease. Neurosci. Lett., 2007, 420, 257-262.
200. Simon-Sanchez, J.; Schulte, C.; Bras, J.M.; Sharma, M.; Gibbs, J.R.; Berg, D.; Paisan-Ruiz, C.; Lichtner, P.; Scholz, S.W.; Hernandez, D.G.; Kruger, R.; Federoff, M.; Klein, C.; Goate, A.; Perlmutter, J.; Bonin, M.; Nalls, M.A.; Illig, T.; Gieger, C.; Houlden, H.; Steffens, M.; Okun, M.S.; Racette, B.A.; Cookson, M.R.; Foote, K.D.; Fernandez, H.H.; Traynor, B.J.; Schreiber, S.; Arepalli, S.; Zonozi, R.; Gwinn, K.; van der Brug, M.; Lopez, G.; Chanock, S.J.; Schatzkin, A.; Park, Y.; Hollenbeck, A.; Gao, J.; Huang, X.; Wood, N.W.; Lorenz, D.; Deuschl, G.; Chen, H.; Riess, O.; Hardy, J.A.; Singleton, A.B.; Gasser, T. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet., 2009, 41, 1308-1312.
201. Pankratz, N.; Wilk, J.B.; Latourelle, J.C.; DeStefano, A.L.; Halter, C.; Pugh, E.W.; Doheny, K.F.; Gusella, J.F.; Nichols, W.C.; Foroud, T.; Myers, R.H. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum. Genet, 2009, 124, 593-605.
202. Gunther, C.; von Hadeln, K.; Muller-Thomsen, T.; Alberici, A.; Binetti, G.; Hock, C.; Nitsch, R.M.; Stoppe, G.; Reiss, J.; Gal, A.; Finckh, U. Possible association of mitochondrial transcription factor A (TFAM) genotype with sporadic Alzheimer disease. Neurosci. Lett., 2004, 369, 219-223.
203. Abahuni, N.; Gispert, S.; Bauer, P.; Riess, O.; Kruger, R.; Becker, T.; Auburger, G. Mitochondrial translation initiation factor 3 gene polymorphism associated with Parkinson's disease. Neurosci. Lett., 2007, 414, 126-129.
204. Behrouz, B.; Vilarino-Guell, C.; Heckman, M.G.; Soto-Ortolaza, A.I.; Aasly, J.O.; Sando, S.; Lynch, T.; Craig, D.; Uitti, R.J.; Wszolek, Z.K.; Ross, O.A.; Farrer, M.J. Mitochondrial translation initiation factor 3 polymorphism and Parkinson's disease. Neurosci. Lett., 2010, 486, 228-230.
205. Anvret, A.; Ran, C.; Westerlund, M.; Thelander, A.C.; Sydow, O.; Lind, C.; Hakansson, A.; Nissbrandt, H.; Galter, D.; Belin, A.C. Possible involvement of a mitochondrial translation initiation factor 3 variant causing decreased mRNA levels in Parkinson's disease. Parkinsons. Dis., 2010, 2010, 491751.
206. Baloh, R.H.; Salavaggione, E.; Milbrandt, J.; Pestronk, A. Familial parkinsonism and ophthalmoplegia from a mutation in the mitochondrial DNA helicase twinkle. Arch Neurol., 2007, 64, 998-1000.
207. Davidzon, G.; Greene, P.; Mancuso, M.; Klos, K.J.; Ahlskog, J.E.; Hirano, M.; DiMauro, S. Early-onset familial parkinsonism due to POLG mutations. Ann. Neurol., 2006, 59, 859-862.
208. Luoma, P.; Melberg, A.; Rinne, J.O.; Kaukonen, J.A.; Nupponen, N.N.; Chalmers, R.M.; Oldfors, A.; Rautakorpi, I.; Peltonen, L.; Majamaa, K.; Somer, H.; Suomalainen, A. Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Lancet, 2004, 364, 875-882.
209. Hudson, G.; Schaefer, A.M.; Taylor, R.W.; Tiangyou, W.; Gibson, A.; Venables, G.; Griffiths, P.; Burn, D.J.; Turnbull, D.M.; Chinnery, P.F. Mutation of the linker region of the polymerase gamma-1 (POLG1) gene associated with progressive external ophthalmoplegia and Parkinsonism. Arch Neurol., 2007, 64, 553-557.
210. Orsucci, D.; Caldarazzo Ienco, E.; Mancuso, M.; Siciliano, G. POLG1-related and other "mitochondrial Parkinsonisms": an overview. J. Mol. Neurosci., 2011, 44, 17-24.
211. Tyynismaa, H.; Sembongi, H.; Bokori-Brown, M.; Granycome, C.; Ashley, N.; Poulton, J.; Jalanko, A.; Spelbrink, J.N.; Holt, I.J.; Suomalainen, A. Twinkle helicase is essential for mtDNA maintenance and regulates mtDNA copy number. Hum. Mol. Genet., 2004, 13, 3219-3227.
212. Spelbrink, J.N.; Li, F.Y.; Tiranti, V.; Nikali, K.; Yuan, Q.P.; Tariq, M.; Wanrooij, S.; Garrido, N.; Comi, G.; Morandi, L.; Santoro, L.; Toscano, A.; Fabrizi, G.M.; Somer, H.; Croxen, R.; Beeson, D.; Poulton, J.; Suomalainen, A.; Jacobs, H.T.; Zeviani, M.; Larsson, C. Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria. Nat. Genet., 2001, 28, 223-231.
213. Kaguni, L.S. DNA polymerase gamma, the mitochondrial replicase. Annu. Rev. Biochem., 2004, 73, 293-320.
214. Graziewicz, M.A.; Longley, M.J.; Copeland, W.C. DNA polymerase gamma in mitochondrial DNA replication and repair. Chem. Rev., 2006, 106, 383-405.
215. Luoma, P.T.; Eerola, J.; Ahola, S.; Hakonen, A.H.; Hellstrom, O.; Kivisto, K.T.; Tienari, P.J.; Suomalainen, A. Mitochondrial DNA polymerase gamma variants in idiopathic sporadic Parkinson disease. Neurology, 2007, 69, 1152-1159.
216. Eerola, J.; Luoma, P.T.; Peuralinna, T.; Scholz, S.; Paisan-Ruiz, C.; Suomalainen, A.; Singleton, A.B.; Tienari, P.J. POLG1 polyglutamine tract variants associated with Parkinson's disease. Neurosci. Lett., 2010, 477, 1-5.
217. Anvret, A.; Westerlund, M.; Sydow, O.; Willows, T.; Lind, C.; Galter, D.; Belin, A.C. Variations of the CAG trinucleotide repeat in DNA polymerase gamma (POLG1) is associated with Parkinson's disease in Sweden. Neurosci. Lett., 2010, 485, 117-120.
218. Balafkan, N.; Tzoulis, C.; Muller, B.; Haugarvoll, K.; Tysnes, O.B.; Larsen, J.P.; Bindoff, L.A. Number of CAG repeats in POLG1 and its association with Parkinson disease in the Norwegian population. Mitochondrion, 2012, 12(6), 640-643.
219. Hudson, G.; Tiangyou, W.; Stutt, A.; Eccles, M.; Robinson, L.; Burn, D.J.; Chinnery, P.F. No association between common POLG1 variants and sporadic idiopathic Parkinson's disease. Mov. Disord., 2009, 24, 1092-1094.
220. Spelbrink, J.N.; Toivonen, J.M.; Hakkaart, G.A.; Kurkela, J.M.; Cooper, H.M.; Lehtinen, S.K.; Lecrenier, N.; Back, J.W.; Speijer, D.; Foury, F.; Jacobs, H.T. In vivo functional analysis of the human mitochondrial DNA polymerase POLG expressed in cultured human cells. J. Biol. Chem., 2000, 275, 24818-24828.
221. Gaweda-Walerych, K.; Safranow, K.; Jasinska-Myga, B.; Bialecka, M.; Klodowska-Duda, G.; Rudzinska, M.; Czyzewski, K.; Cobb, S.A.; Slawek, J.; Styczynska, M.; Opala, G.; Drozdzik, M.; Nishioka, K.; Farrer, M.J.; Ross, O.A.; Wszolek, Z.K.; Barcikowska, M.; Zekanowski, C. PARK2 variability in Polish Parkinson's disease patients-interaction with mitochondrial haplogroups. Parkinsonism. Relat. Disord., 2012, 18, 520-524.
222. Lucking, C.B.; Chesneau, V.; Lohmann, E.; Verpillat, P.; Dulac, C.; Bonnet, A.M.; Gasparini, F.; Agid, Y.; Durr, A.; Brice, A. Coding polymorphisms in the parkin gene and susceptibility to Parkinson disease. Arch. Neurol., 2003, 60, 1253-1256.
223. Wu, Y.R.; Wu, C.H.; Chao, C.Y.; Kuan, C.C.; Zhang, W.L.; Wang, C.K.; Chang, C.Y.; Chang, Y.C.; Lee-Chen, G.J.; Chen, C.M. Genetic analysis of Parkin in early onset Parkinson's disease (PD): Novel intron 9 g > a single nucleotide polymorphism and risk of Taiwanese PD. Am. J. Med. Genet. B Neuropsychiatr. Genet, 2010, 153B, 229-234.
224. Aguiar Pde, C.; Lessa, P.S.; Godeiro, C., Jr.; Barsottini, O.; Felicio, A.C.; Borges, V.; Silva, S.M.; Saba, R.A.; Ferraz, H.B.; Moreira-Filho, C.A.; Andrade, L.A. Genetic and environmental findings in early-onset Parkinson's disease Brazilian patients. Mov. Disord., 2008, 23, 1228-1233.
225. Wittkopp, S.; Staimer, N.; Tjoa, T.; Gillen, D.; Daher, N.; Shafer, M.; Schauer, J.J.; Sioutas, C.; Delfino, R.J. Mitochondrial genetic background modifies the relationship between traffic-related air pollution exposure and systemic biomarkers of inflammation. PLoS One, 2013, 8, e64444.
226. Henchcliffe, C.; Beal, M.F. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat. Clin. Pract. Neurol., 2008, 4, 600-609.
227. Pihlstrom, L.; Axelsson, G.; Bjornara, K.A.; Dizdar, N.; Fardell, C.; Forsgren, L.; Holmberg, B.; Larsen, J.P.; Linder, J.; Nissbrandt, H.; Tysnes, O.B.; Ohman, E.; Dietrichs, E.; Toft, M. Supportive evidence for 11 loci from genome-wide association studies in Parkinson's disease. Neurobiol. Aging, 2012, 34(6), 1708. e7-13
228. Liu, X.; Cheng, R.; Verbitsky, M.; Kisselev, S.; Browne, A.; Mejia-Sanatana, H.; Louis, E.D.; Cote, L.J.; Andrews, H.; Waters, C.; Ford, B.; Frucht, S.; Fahn, S.; Marder, K.; Clark, L.N.; Lee, J.H. Genome-wide association study identifies candidate genes for Parkinson's disease in an Ashkenazi Jewish population. BMC Med. Genet, 2011, 12, 104.
229. Sharma, M.; Ioannidis, J.P.; Aasly, J.O.; Annesi, G.; Brice, A.; Van Broeckhoven, C.; Bertram, L.; Bozi, M.; Crosiers, D.; Clarke, C.; Facheris, M.; Farrer, M.; Garraux, G.; Gispert, S.; Auburger, G.; Vilarino-Guell, C.; Hadjigeorgiou, G.M.; Hicks, A.A.; Hattori, N.; Jeon, B.; Lesage, S.; Lill, C.M.; Lin, J.J.; Lynch, T.; Lichtner, P.; Lang, A.E.; Mok, V.; Jasinska-Myga, B.; Mellick, G.D.; Morrison, K.E.; Opala, G.; Pramstaller, P.P.; Pichler, I.; Park, S.S.; Quattrone, A.; Rogaeva, E.; Ross, O.A.; Stefanis, L.; Stockton, J.D.; Satake, W.; Silburn, P.A.; Theuns, J.; Tan, E.K.; Toda, T.; Tomiyama, H.; Uitti, R.J.; Wirdefeldt, K.; Wszolek, Z.; Xiromerisiou, G.; Yueh, K.C.; Zhao, Y.; Gasser, T.; Maraganore, D.; Kruger, R. Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology, 2012, 79, 659-667.
230. Trotta, L.; Guella, I.; Solda, G.; Sironi, F.; Tesei, S.; Canesi, M.; Pezzoli, G.; Goldwurm, S.; Duga, S.; Asselta, R. SNCA and MAPT genes: Independent and joint effects in Parkinson disease in the Italian population. Parkinsonism. Relat. Disord., 2012, 18, 257-262.
231. Ding, H.; Sarokhan, A.K.; Roderick, S.S.; Bakshi, R.; Maher, N.E.; Ashourian, P.; Kan, C.G.; Chang, S.; Santarlasci, A.; Swords, K.E.; Ravina, B.M.; Hayes, M.T.; Sohur, U.S.; Wills, A.M.; Flaherty, A.W.; Unni, V.K.; Hung, A.Y.; Selkoe, D.J.; Schwarzschild, M.A.; Schlossmacher, M.G.; Sudarsky, L.R.; Growdon, J.H.; Ivinson, A.J.; Hyman, B.T.; Scherzer, C.R. Association of SNCA with Parkinson: replication in the Harvard NeuroDiscovery Center Biomarker Study. Mov. Disord., 2011, 26, 2283-2286.
232. Mata, I.F.; Yearout, D.; Alvarez, V.; Coto, E.; de Mena, L.; Ribacoba, R.; Lorenzo-Betancor, O.; Samaranch, L.; Pastor, P.; Cervantes, S.; Infante, J.; Garcia-Gorostiaga, I.; Sierra, M.; Combarros, O.; Snapinn, K.W.; Edwards, K.L.; Zabetian, C.P. Replication of MAPT and SNCA, but not PARK16-18, as susceptibility genes for Parkinson's disease. Mov. Disord., 2011, 26, 819-823.
233. Simon-Sanchez, J.; van Hilten, J.J.; van de Warrenburg, B.; Post, B.; Berendse, H.W.; Arepalli, S.; Hernandez, D.G.; de Bie, R.M.; Velseboer, D.; Scheffer, H.; Bloem, B.; van Dijk, K.D.; Rivadeneira, F.; Hofman, A.; Uitterlinden, A.G.; Rizzu, P.; Bochdanovits, Z.; Singleton, A.B.; Heutink, P. Genome-wide association study confirms extant PD risk loci among the Dutch. Eur. J. Hum. Genet, 2011, 19, 655-661.
234. Rhodes, S.L.; Sinsheimer, J.S.; Bordelon, Y.; Bronstein, J.M.; Ritz, B. Replication of GWAS associations for GAK and MAPT in Parkinson's disease. Ann. Hum. Genet, 2011, 75, 195-200.
235. Tan, E.K.; Kwok, H.H.; Tan, L.C.; Zhao, W.T.; Prakash, K.M.; Au, W.L.; Pavanni, R.; Ng, Y.Y.; Satake, W.; Zhao, Y.; Toda, T.; Liu, J.J. Analysis of GWAS-linked loci in Parkinson disease reaffirms PARK16 as a susceptibility locus. Neurology, 2010, 75, 508-512.
236. Satake, W.; Nakabayashi, Y.; Mizuta, I.; Hirota, Y.; Ito, C.; Kubo, M.; Kawaguchi, T.; Tsunoda, T.; Watanabe, M.; Takeda, A.; Tomiyama, H.; Nakashima, K.; Hasegawa, K.; Obata, F.; Yoshikawa, T.; Kawakami, H.; Sakoda, S.; Yamamoto, M.; Hattori, N.; Murata, M.; Nakamura, Y.; Toda, T. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet, 2009, 41, 1303-1307.
237. Tsuboi, Y. Environmental-genetic interactions in the pathogenesis of Parkinson's disease. Exp. Neurobiol., 2012, 21, 123-128.
238. Berg, D. Is pre-motor diagnosis possible?-The European experience. Parkinsonism. Relat. Disord., 2012, 18 Suppl 1, S195-198.